El interés en corto de Moderna da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Moderna. Los datos de interés en corto se actualizan cada dos semanas.

Moderna (NASDAQ:MRNA) Bolsa, Informe de interés en corto

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna Inc

MODERNA ORD

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 44 trades.
If we consider the specifics of each trade, it is accurate to state that 63% of the investors opened trades with bullish expectations and 29% with bearish.
From the overall spotted trades, 30 are puts, for a total amount of $2,727,271 and 14, calls, for a total amount of $652,606.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $175.0 for Moderna over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1078.22 with a total volume of 29,102.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $40.0 to $175.0 over the last 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727901128_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$8.25</td>
<td>$8.0</td>
<td>$8.05</td>
<td>$55.00</td>
<td>$1.0M</td>
<td>1.4K</td>
<td>1.2K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.9</td>
<td>$22.0</td>
<td>$22.4</td>
<td>$75.00</td>
<td>$232.9K</td>
<td>1.3K</td>
<td>104</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.15</td>
<td>$5.75</td>
<td>$6.05</td>
<td>$50.00</td>
<td>$229.2K</td>
<td>1.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$8.9</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$95.00</td>
<td>$138.6K</td>
<td>5</td>
<td>198</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$37.4</td>
<td>$37.3</td>
<td>$37.4</td>
<td>$100.00</td>
<td>$127.1K</td>
<td>3.5K</td>
<td>34</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>Trading volume stands at 4,087,379, with MRNA's price down by -1.17%, positioned at $63.18.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

MRNA

Moderna Unusual Options Activity For October 02

Pfizer Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) made a promise&nbsp;to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) in turning to oncology for its next growth story. Both Moderna and Pfizer made history during the COVID-19 pandemic thanks to mRNA technology. Now, Moderna and Pfizer embarked on a journey to treat cancer with mRNA science. By using mRNA-based next-generation CRC screening tests, a much smaller and less known pharma player,&nbsp;Mainz Biomed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>), is already redefining standards in early cancer detection with its flagship colorectal cancer test ColoAlert, while also tackling cancer prevention.
<h3>Moderna Has Several Oncology Trials In Motion</h3>
First, there is the collaboration with Merck &amp;Co Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>). The combination of&nbsp;immunotherapy blockbuster drug Keytruda from Merck and the&nbsp;experimental mRNA vaccine showed encouraging results in patients diagnosed with melanoma, a deadly form of skin cancer. During summer, Merck and Moderna released positive mid-stage results that showed improved survival rates and showed long-lasting efficacy. Along with targeting melanoma by joining forces with Merck, Moderna is also conducting clinical trials of a cancer treatment for adults diagnosed with solid tumor cancers, lymphoma and non-small lung cancer.&nbsp;&nbsp;
<h3>Mainz Biomed Is Gearing Up To Revolutionize Early Cancer Detection</h3>
Determined to lead the way in cancer diagnostics, Mainz Biomed opened the week by releasing a statement to shareholders that highlighted its strategic plans,&nbsp;clinical developments, and its upcoming FDA trial anticipated for 2025 which should pave the way for entry into the U.S. market.&nbsp;With its innovative diagnostic solution ColoAlert that is already marketed across Europe, Mainz&nbsp;Biomed&nbsp;has positioned itself for substantial growth in global markets next year.&nbsp;With its&nbsp;flagship non-invasive test that not only revolutionized early detection of colorectal cancer but also prevention by identifying precancerous lesions, particularly advanced adenomas, Mainz Biomed reported significant clinical success in both US and European trials. Identifying these lesions allows for timely intervention through colonoscopy and adenoma removal, thereby warding off cancer from developing in the first place.
In addition to its mRNA next generation CRC screening test,&nbsp;Mainz&nbsp;Biomed&nbsp;is also developing PancAlert for an easy and convenient at home test for pancreatic cancer.
Tackling A&nbsp;fight that modern medicine just cannot seem to win.
Despite its efforts to translate scientific research into effective medicines for cancer patients, Pfizer is still not near a breakthrough in oncology. Undoubtably, Pfizer is betting big on oncology to turn its ship around, which it showed with the&nbsp;$43 billion acquisition of the cancer drugmaker Seagen. With the combined pipeline,&nbsp;Pfizer is hoping to produce at least eight blockbuster medicines by the end of the decade. But this is still only a promise while&nbsp;cancer remains one of the most complex diseases of the modern civilization and one of science&rsquo;s biggest challenges. Only time will show if mRNA technology is the missing piece of the puzzle for science to finally win the cancer battle. While no one knows if the COVID-19 success of mRNA science&nbsp;can be replicated for cancer, it does seem it is a good enough of a tool to make some much needed breakthroughs.&nbsp;
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Biotech

Penny Stocks

General

MYNZ

The Covid Era Tech Promises To Reinvent Cancer Treatment

Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Cenra Healthcare, the sales and marketing arm of Cenra Inc., today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Taiwan, including Moderna's COVID-19 vaccine, Spikevax&#xAE;.
Under the agreement, Moderna will manufacture and distribute its mRNA respiratory vaccines. Cenra Healthcare will engage in promotion and execute medical education activities to ensure broad access to Moderna's mRNA respiratory portfolio across Taiwan. The agreement has an initial term until July 31, 2027, and no further details on the financial terms of the deal are being disclosed.

Government

News

Regulations

Reported Earlier, Moderna and Cenra Healthcare Join Forces to Promote COVID-19 and Respiratory Vaccines in Taiwan

Large Cap

Health Care

Moderna Has Dosed The First US Participant In Nova 301 Phase 3 Trial Evaluating The Efficacy, Safety, And Immunogenicity Of An Investigational Norovirus Vaccine, mRNA-1403. Global Recruitment For Nova 301 Trial Has Also Begun

Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) has outperformed the market over the past 5 years by 18.39% on an annualized basis producing an average annual return of 32.37%. Currently, Moderna has a market capitalization of $24.87 billion. 
Buying $100 In MRNA: If an investor had bought $100 of MRNA stock 5 years ago, it would be worth $406.92 today based on a price of $64.70 for MRNA at the time of writing.
<h3>Moderna's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727200826_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Moderna 5 Years Ago Would Be Worth Today

<a href="https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.">https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.</a>
&nbsp;
Los Angeles County health officials are reporting a significant uptick in mpox cases, prompting renewed calls for vaccination among&nbsp;high-risk&nbsp;groups.
The County's Department of Public Health announced that 52 mpox cases were reported in the past four weeks, compared to 24 in the previous&nbsp;four-week&nbsp;period.&nbsp;
About 70% of new cases in the last six months occurred in&nbsp;unvaccinated&nbsp;individuals.
Health officials strongly recommend vaccination for several high-risk groups, including men and transgender people who have sex with men or transgender persons, persons of any gender or sexual orientation who have sex or intimate physical contact with others in association with large public events or engage in commercial and/or transactional sex, and those living&nbsp;with&nbsp;HIV.
"Vaccination is an important tool in preventing the spread of mpox," the County health department said in a statement. The two-dose JYNNEOS vaccine is available at pharmacies for insured residents and at Los Angeles County Department of Public Health Clinics for free&nbsp;without&nbsp;appointments.
Officials advise residents to practice safe sex, limit sexual partners, and avoid intimate contact with anyone showing mpox symptoms, which include rash, fever, and swollen lymph nodes. Additional prevention measures include asking partners about symptoms, reducing the number of partners, and proper use of condoms&nbsp;and&nbsp;gloves.
The County emphasizes the importance of testing for those who develop symptoms consistent with mpox. The Department of Public Health is collaborating with healthcare providers and community organizations to intensify surveillance, contact tracing, and outbreak investigations to&nbsp;curb&nbsp;transmission.
Mpox, previously referred to as Monkeypox, is mainly spread through close physical contact. Residents seeking more information can visit<a href="http://ph.lacounty.gov/mpox"> ph.lacounty.gov/mpox</a> or call the Department of Public Health Call Center&nbsp;at&nbsp;1-833-540-0473.

Macro Economic Events

Economics

AEMD

APDN

CMRX

GOVX

TNXP

VRAX

'Mpox Cases Double In Los Angeles County, Health Officials Urge Vaccination; Los Angeles County Public Health Officials Report Increase, Recommend Prevention Measures' - Pasadena Now

<a href="https://www.youtube.com/watch?v=ZFW3ONApp4w" title="https://www.youtube.com/watch?v=ZFW3ONApp4w">https://www.youtube.com/watch?v=ZFW3ONApp4w</a>

Macro Notification

Biden On Sudan Says End This War Now; Let's Move Quickly To Face Mpox Outbreak In Africa

-Reuters Citing Senior Administration Official

President Biden Will Announce Donation Of 1M MPox Vaccine Doses, At Least $500M To African Countries To Support Their Response To Outbreak

CDC Says No Cases Of Clade IA Mpox Have Been Reported Outside Central African Countries Where Clade IA MPVX Is Endemic

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Progyny Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>)</h3>
<ul>
<li>On Sept. 19, the company said a client elected to exercise an option to terminate its services agreement with the company. The company's stock fell around 32% over the past five days and has a <a href="https://www.benzinga.com/quote/PGNY">52-week low of $13.93</a>.</li>
<li>RSI Value: 26.50</li>
<li>PGNY Price Action: Shares of Progyny rose 1% to close at $16.62 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"> latest PGNY news.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="895" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071143/image-171.png" alt="" class="wp-image-560811" style="width:671px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071143/image-171.png 895w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071143/image-171-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071143/image-171-768x721.png 768w" sizes="(max-width: 895px) 100vw, 895px" /></a></figure>
<h3 class="wp-block-heading">Indivior PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Sept. 4, Indivior issued an update on Aelis Farma&#8217;s Phase 2B study with AEF0117 in participants with cannabis use disorder. It <a href="https://www.benzinga.com/quote/INDV">has a 52-week low</a> of $9.14.</li>
<li>RSI Value: 25.92</li>
<li>RELI Price Action: Shares of Indivior fell 2.1% to close at $9.48 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"> trend in INDV stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071157/image-172.png" alt="" class="wp-image-560812" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071157/image-172.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071157/image-172-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071157/image-172-768x717.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</h3>
<ul>
<li>On Sept. 17, Moderna announced that Health Canada approved its vaccine, SPIKEVAX, which aids in preventing COVID-19 in people six months of age or older.The vaccine targets the KP.2 variant of COVID-19. The company plans to begin delivery of the vaccine to the Public Health Agency of Canada shortly. "With the recent increase in COVID-19-infections, staying up to date with your COVID-19 vaccination remains one of the best ways to help protect yourself from severe illness," said Dr. Shehzad Iqbal, country medical director, Moderna Canada. The company's shares fell around 20% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/MRNA">low of $62.55</a>.</li>
<li>RSI Value: 28.17</li>
<li>MRNA Price Action: Shares of Moderna fell 3.4% to close at $65.69 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1">breakout in MRNA shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071229/image-173.png" alt="" class="wp-image-560813" style="width:610px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071229/image-173.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071229/image-173-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071229/image-173-768x710.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
Read Next:<a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

Long Ideas

Pre-Market Outlook

INDV

PGNY

Top 3 Health Care Stocks That May Explode This Month

Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) revealed 22 unusual trades.
Delving into the details, we found 31% of traders were bullish, while 54% showed bearish tendencies. Out of all the trades we spotted, 13 were puts, with a value of $4,197,475, and 9 were calls, valued at $516,749.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $120.0 for Moderna over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Moderna's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale trades within a strike price range from $50.0 to $120.0 in the last 30 days. 
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726863434_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$55.0</td>
<td>$54.25</td>
<td>$54.5</td>
<td>$120.00</td>
<td>$1.3M</td>
<td style="text-align: right;">46</td>
<td style="text-align: right;">752</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$55.0</td>
<td>$54.75</td>
<td>$55.0</td>
<td>$120.00</td>
<td>$1.0M</td>
<td style="text-align: right;">46</td>
<td style="text-align: right;">952</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$54.15</td>
<td>$54.1</td>
<td>$54.15</td>
<td>$120.00</td>
<td>$552.3K</td>
<td style="text-align: right;">46</td>
<td style="text-align: right;">102</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$54.05</td>
<td>$54.0</td>
<td>$54.05</td>
<td>$120.00</td>
<td>$502.6K</td>
<td style="text-align: right;">46</td>
<td style="text-align: right;">272</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$19.05</td>
<td>$16.6</td>
<td>$18.45</td>
<td>$65.00</td>
<td>$276.7K</td>
<td style="text-align: right;">104</td>
<td style="text-align: right;">150</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Having examined the options trading patterns of Moderna, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Moderna</h3>
<ul>
<li>Trading volume stands at 12,030,554, with MRNA's price down by -3.43%, positioned at $65.69.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 41 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Moderna options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Moderna Unusual Options Activity For September 20

On Saturday, Pfizer Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) presented positive trial data for experimental drug designed for patients suffering from&nbsp;cancer cachexia during the European Society for Medical Oncology 2024 Congress. Affecting as many as&nbsp;9 million people across the globe, cancer cachexia is a life-threatening condition that causes cancer patients to lose appetite and consequently, weight.
<h3>Paving The Way For The World&rsquo;s First Treatment For Cancer Cachexia</h3>
The mid-stage trial results showed that patients that were treated with the experimental drug that Pfizer developed showed improvements in body weight, muscle mass, quality of life and physical function. Therefore, the drug which is a monoclonal antibody called ponsegromab could become the first treatment approved in the U.S. specifically&nbsp;for this condition. This would translate to Pfizer saving many lives as 80% of cancer patients who suffer from this condition are not expected to make it beyond a year of being diagnosed as they are unable to meet their body&rsquo;s energy and nutritional needs. The condition also makes the general treatment of cancer less effective and lowers the odds of survival as it leaves the patient even weaker, unable to tolerate the treatment.&nbsp;
<h3>The Trial</h3>
Involving&nbsp;187 patients diagnosed with non-small cell lung cancer, pancreatic cancer or colorectal cancer and high levels of a key driver of cachexia, patients who took the highest dose of ponsegromab, which is 400 milligrams, over the course of 12 weeks&nbsp;observed a&nbsp;5.6% increase in weight compared to those patients who received a placebo. Patients who took lower doses of 200 or 100-milligrams observed roughly 3.5% and 2% increase in body weight compared to the placebo group. Pfizer added that experts consider weight gain greater than 5% as a &ldquo;clinically meaningful difference&rdquo; when it comes to cancer patients with cachexia and noted that increased appetite and improvement in physical activity is what was most encouraging.&nbsp;&nbsp;The good news is that no significant side effects of the drug were observed. Pfizer is planning to begin late-stage development studies in 2025 that can be used to file for approval, while also studying the effect of ponsegromab in a phase two trial in patients diagnosed with heart failure.
Catching up to Moderna Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) and others on the cancer front.
It&rsquo;s no secret that Pfizer has turned to oncology in an effort to combat the Covid-19 decline.&nbsp;&nbsp;To turn its business around, it targeted as many as 8 blockbuster cancer drugs by the end of this decade. One of its main Covid-19 rivals, Moderna is expected to launch its experimental cancer vaccine as early as next year.
Together with Merck &amp; Co Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>), Moderna is currently testing their combined treatment for advanced melanoma in a large-scale Phase III trial. Approximately, 1,089 patients at more than 165 sites across the globe will be tested to assess the efficiency of the experimental vaccine mRNA-4157 that Moderna and Merck co-developed, along with the immunotherapy drug, Keytruda, that is already a blockbuster for Merck. The study will assess the efficiency of the treatment that Moderna and Merck created in achieving a recurrence-free survival, while the secondary endpoints are distant metastasis-free survival, along with overall survival and safety.
&nbsp;
Codenamed mRNA-4359, Moderna also designed a vaccine to boost people&#39;s immunity to better recognize and fight a variety of advanced solid tumor cancers. During the above-mentioned congress that took place in Barcelona, Spain, on Saturday, researchers at King&rsquo;s College London&nbsp;presented&nbsp;Phase I/II trial to test Moderna&rsquo;s vaccine candidate, more precisely its ability to sensitize the immune system to two specific proteins commonly common in tumor cells as well as other cells that suppress the immune system, PD-L1 and IDO1.&nbsp;From 16 patients diagnosed with advanced lung cancer, melanoma, and other solid tumors who were able to have their responses measured, eight patients showed no signs of their tumors growing and there were no new tumors formed. In addition, tests found that the vaccine seemed to generate a noticeable increase in immune cells that could recognize PD-L1 and IDO1.&nbsp;While more data will be needed to know whether mRNA-4359 can work as hoped, these results are promising.&nbsp;
The future of cancer treatment looks bright.
Besides vaccines designed to help patients combat cancer, Mainz Biomed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>) advanced on the early screening and prevention front. A molecular genetics diagnostic company specialized in the early detection of cancer,&nbsp;Mainz Biomed is currently seeking FDA approval for its colorectal cancer test, ColoAlert. With an innovative portfolio of mRNA biomarkers, Mainz Biomed is promising to set a new gold standard for noninvasive detection of advanced adenoma, which is a well-known pre-cancerous condition. This week, Mainz Biomed announced its newest Brand Ambassador,&nbsp;Petra Smeltzer Starke, known serving as&nbsp;General Counsel to the White House Council of Economic Advisors and Senior Advisor to President Obama. Ms. Smeltzer Starke&rsquo;s role will be to help to raise awareness on the importance of early detection of colorectal cancer. If diagnosed early, up to 90% of colorectal cancer cases can be treated successfully. Therefore, early screening makes all the difference.&nbsp;
By the looks of it, years ahead seem promising when it comes to revolutionizing cancer treatment.&nbsp;
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Eurozone

Pfizer Advances On Its Cancer Journey

CHMP Gave Positive Opinions To Update The Composition Of The Moderna's MRNA Vaccine Spikevax1, To Target SARS-COV-2 JN.1 Variant Of The Virus That Causes Covid-19

Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $562,711, and 5 were calls, valued at $259,716.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $60.0 to $100.0 for Moderna during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of 2,026.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $60.0 to $100.0 over the last 30 days.
<h3>Moderna Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726777077_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$25.9</td>
<td>$24.35</td>
<td>$25.9</td>
<td>$90.00</td>
<td>$388.5K</td>
<td>1.9K</td>
<td style="text-align: right;">150</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$13.3</td>
<td>$13.25</td>
<td>$13.3</td>
<td>$70.00</td>
<td>$81.1K</td>
<td>108</td>
<td style="text-align: right;">123</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$31.0</td>
<td>$30.85</td>
<td>$31.0</td>
<td>$100.00</td>
<td>$65.1K</td>
<td>0</td>
<td style="text-align: right;">609</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.66</td>
<td>$2.65</td>
<td>$2.65</td>
<td>$60.00</td>
<td>$59.3K</td>
<td>1.6K</td>
<td style="text-align: right;">233</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.55</td>
<td>$80.00</td>
<td>$58.5K</td>
<td>702</td>
<td style="text-align: right;">536</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>Trading volume stands at 5,013,059, with MRNA's price down by -2.52%, positioned at $68.1.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 42 days.</li>
</ul>
<h3>What Analysts Are Saying About Moderna</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $82.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Sector Perform, setting a price target of $75. 
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Moderna, which currently sits at a price target of $75. 
&#x2A; An analyst from Jefferies has revised its rating downward to Hold, adjusting the price target to $65. 
&#x2A; An analyst from HSBC upgraded its action to Hold with a price target of $82. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Moderna, targeting a price of $115. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Behind the Scenes of Moderna's Latest Options Trends

<a href="https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.">https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.</a>
&nbsp;
EMA has recommended extending the indication of the smallpox and mpox vaccine <a href="https://www.ema.europa.eu/node/65501">Imvanex</a> to adolescents from 12 to 17 years of age.
Imvanex is already authorised in the European Union (EU) to protect against smallpox, mpox and the disease caused by the vaccinia virus in adults. It contains a live, highly weakened form of a virus called "modified vaccinia virus Ankara" (MVA-BN), which is related to the smallpox virus. EMA's human medicines committee (CHMP) based the recommendation to extend the use of Imvanex to adolescents on the <a href="https://www.clinicaltrials.gov/study/NCT05740982">interim results of a study</a> that compared the vaccine's ability to generate an immune response (produce virus-specific antibodies) in 315 adolescents and in 211 adults.
The immune response in adolescents was similar to adults. Therefore, it is inferred that the vaccine will provide similar protection in adolescents to that expected in adults. According to the submitted data, the safety profile of Imvanex in adolescents was comparable to that seen in adults and no additional risk has been identified. As part of its recommendation, EMA has requested the marketing authorisation holder to submit the final results of the study by 30 May 2025 to further characterise the information about safety in adolescents.
The Agency's assessment has important implications for the global response to the mpox outbreak in the Democratic Republic of the Congo (DRC) and other countries, which was <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern">declared a public health emergency of international concern (PHEIC)</a> by the World Health Organization (WHO) on 14 August 2024.
EMA is the regulatory agency of record for <a href="https://www.who.int/news/item/13-09-2024-who-prequalifies-the-first-vaccine-against-mpox">prequalification of this vaccine by WHO</a> on 13 September 2024. This means that CHMP's assessment constitutes the basis for WHO prequalification approval to facilitate timely and increased access to this vaccine in communities with urgent need. Previously, EMA's assessment was also taken into account by the national regulatory authority of the DRC in the fast-track approval of the vaccine. In addition, WHO has cooperated in EMA's assessment of the extension of indication in adolescents, a population that is particularly vulnerable to mpox.
Mpox is a disease that is transmitted to people by animals, mainly rodents, but can also spread between people with direct contact. It is endemic in certain parts of Central and West Africa. The current surge in cases in the DRC and several neighbouring countries is driven by the mpox clade I strain that is known to cause a more severe form of mpox in humans than the mpox clade II strain that spread during the 2022/2023 PHEIC. Mpox can be fatal for people with weak immune systems.
Data indicate that Imvanex protects against both the clade I and clade II mpox strains.
In the EU, decisions on how vaccinations should be given are the prerogative of the expert bodies guiding vaccination campaigns in each Member State. The European Centre for Disease Prevention and Control (ECDC) <a href="https://www.ecdc.europa.eu/en/infectious-disease-topics/mpox/rapid-scientific-advice-public-health-measures-mpox-2024">published advice for public health authorities for mpox</a> on their website.

Global

'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA

RBC Capital analyst Luca Issi reiterates Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Sector Perform and maintains $75 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Sector Perform on Moderna, Maintains $75 Price Target

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$65.0K</td>
<td>37.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>814</td>
<td>482</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$130.00</td>
<td>$25.3K</td>
<td>972</td>
<td>303</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$196.0K</td>
<td>7</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$62.50</td>
<td>$90.0K</td>
<td>1.0K</td>
<td>200</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$128.00</td>
<td>$32.6K</td>
<td>6</td>
<td>200</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$105.3K</td>
<td>561</td>
<td>174</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$155.00</td>
<td>$55.5K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$380.00</td>
<td>$98.7K</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>RPRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$50.2K</td>
<td>43</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 485 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $65.0K, with a price of $325.0 per contract. There were 37533 open contracts at this strike prior to today, and today 2165 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on September 27, 2024. Parties traded 104 contract(s) at a $70.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $252.0 per contract. There were 814 open contracts at this strike prior to today, and today 482 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with bullish sentiment. It expires in 30 day(s) on October 18, 2024. Parties traded 59 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $430.0 per contract. There were 972 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we notice a put option trade that happens to be neutral, expiring in 485 day(s) on January 16, 2026. This event was a transfer of 200 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $196.0K, with a price of $980.0 per contract. There were 7 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option trade that happens to be bullish, expiring in 121 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $90.0K, with a price of $450.0 per contract. There were 1039 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with bearish sentiment. It expires in 2 day(s) on September 20, 2024. Parties traded 102 contract(s) at a $128.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $320.0 per contract. There were 6 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 121 day(s) on January 17, 2025. Parties traded 70 contract(s) at a $315.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $105.3K, with a price of $1505.0 per contract. There were 561 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option trade with bullish sentiment. It expires in 211 day(s) on April 17, 2025. Parties traded 150 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $55.5K, with a price of $370.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 275 day(s) on June 20, 2025. This event was a transfer of 30 contract(s) at a $380.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $3290.0 per contract. There were 10 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• For RPRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), we notice a call option trade that happens to be bullish, expiring in 211 day(s) on April 17, 2025. This event was a transfer of 54 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 43 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGN

AMGN

EXAS

ILMN

RPRX

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he likes Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and recommended <a href="https://www.benzinga.com/quote/PFE/analyst-ratings">buying more of the stock.</a>
On Sept. 16, Cantor Fitzgerald analyst Louise Chen reiterated Pfizer with an Overweight rating and maintained a $45 price target.
&#8220;Six Flags (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>), I don't know, it feels like it's two flags,&#8221; Cramer said. &#8220;This has just been a merger from hell. I'm not really into the stock.&#8221;
On Sept. 16, JPMorgan analyst Matthew Boss maintained Six Flags Entertainment with an Underweight rating and lowered the price target from $48 to $43.
Cramer said he likes First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), adding that it is an &#8220;up stock.&#8221;
On Sept. 16, BofA Securities analyst Julien Dumoulin-Smith maintained First Solar with a Buy and raised the price target from $320 to $343.
The &#8220;Mad Money&#8221; host said Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) is an &#8220;amazing&#8221; stock, and added that it's a &#8220;total winner.&#8221;
On Sept. 16, several analysts, including, Scotiabank, Evercore ISI Group and JPMorgan, raised their price targets on the stock.
Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) has been a &#8220;big disappointment,&#8221; Cramer said.
Moderna announced on Tuesday that Health Canada approved its vaccine, SPIKEVAX, which aids in preventing COVID-19 in people six months of age or older.
&#8220;On a pullback, absolutely,&#8221; Cramer said when asked about Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>). &#8220;I think it's a winner.&#8221;
On Sept. 11, Vertiv named Frank Poncheri as chief human resources officer.
Cramer said Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) is a buy.
On July 30, Powell Industries reported better-than-expected third-quarter GAAP EPS and sales results.
Price Action:
<ul>
<li>Pfizer shares slipped 0.8% to settle at $29.83 on Tuesday.</li>
<li>Powell shares rose 2.5% to close at $174.44 during the session.</li>
<li>First Solar shares rose 2.9% to close at $239.98 during Tuesday's session.</li>
<li>Six Flags shares gained 2.3% to settle at $41.52.</li>
<li>Equity Residential shares fell 0.6% to close at $77.34 on Tuesday.</li>
<li>Moderna shares gained 4.1% to settle at $71.99 on Tuesday.</li>
<li>Vertiv shares gained 0.4% to close at $87.29.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/09/40898216/cramer-hewlett-packard-is-a-very-inexpensive-stock-likes-this-big-tech-stock">Cramer: Hewlett Packard Is A &#8216;Very Inexpensive&#8217; Stock, Likes This Big Tech Stock</a></li>
</ul>
Photo: s_bukley/Shutterstock.com

Media

FSLR

POWL

Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse

The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), hit fresh record highs during Tuesday morning trading and closed up 0.04%, marking its seventh consecutive day of gains, just ahead of the Federal Reserve&#8217;s highly <a href="https://www.benzinga.com/topic/interest-rates">anticipated interest rate decision.</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SPY&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPY</a> hit all-time highs today <a href="https://t.co/MxtEgTXErl">pic.twitter.com/MxtEgTXErl</a>
&mdash; Benzinga (@Benzinga) <a href="https://twitter.com/Benzinga/status/1836051317464178892?ref_src=twsrc%5Etfw">September 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The performance of the index tracking the largest 500 U.S. companies by market capitalization was in line with other major indices. The Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the tech-heavy Nasdaq, and the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) both closed broadly flat for the day.
However, small-cap stocks outperformed their larger counterparts, as the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) finished 0.8% higher.
Policymakers gathered on Tuesday for the two-day Federal Open Market Committee (FOMC) meeting, with the interest rate decision expected on Wednesday at 2:00 p.m. ET.
Market expectations are mixed, with CME FedWatch data indicating a 65% chance of a 50-basis-point rate cut and a 35% chance of a smaller 25-basis-point cut. This level of uncertainty is unusual on the eve of a Fed decision.
Expectations for a larger rate cut fell slightly after August retail sales came in stronger than anticipated. Retail sales increased by 0.1% month-over-month, decelerating from July&#8217;s robust 1.1% growth but beating forecasts of a 0.2% decline.
The unexpected strength in consumer spending has cast some doubt on the need for a significant rate cut to support the economy.
An overwhelming consensus among Wall Street analysts anticipates a 25-basis-point cut, yet JPMorgan Chase stands among the outliers predicting a 50-basis-point reduction.
<h3 class="wp-block-heading">Tuesday&#8217;s Top 5 S&amp;P 500 Stocks</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Sector</td>
<td>1-day Return (%)</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>Information Technology</td>
<td>6.32</td>
</tr>
<tr>
<td>Hewlett Packard Enterprise Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NASDAQ">HPE</a>)</td>
<td>Information Technology</td>
<td>5.66</td>
</tr>
<tr>
<td>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>Health Care</td>
<td>4.05</td>
</tr>
<tr>
<td>Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>)</td>
<td>Financials</td>
<td>4.00</td>
</tr>
<tr>
<td>United Rentals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>)</td>
<td>Industrials</td>
<td>3.95</td>
</tr>
<tr>
<td>Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>)</td>
<td>Consumer Discretionary</td>
<td>3.86</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40908202/10-etfs-investors-secretly-bought-before-the-feds-make-or-break-interest-rate-cal">10 ETFs Investors Secretly Bought Before The Fed&#8217;s Make-Or-Break Interest Rate Call</a></li>
</ul>
Image created using artificial intelligence via Dall-E.

Equities

Mid Cap

Broad U.S. Equity ETFs

Econ #s

Tech

ETFs

ABNB

SPDR Dow Jones Industrial Average ETF Trust

ENPH

S&P 500 Briefly Hits Record High Just Ahead Of Fed Rate Cut, Extends 7-Day Winning Streak: Tuesday's Top 5 Gainers

Wall Street experienced a slightly positive session Tuesday, supported by investor optimism as the Federal Open Market Committee (FOMC) kicked off its two-day meeting, expected to deliver the first interest rate cut in over <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40878710/investors-bet-on-50-basis-point-rate-cut-wall-street-analysts-urge-caution-this-is-">four years on Wednesday.</a>
The session&#8217;s notable performers were small caps, with the Russell 2000 index surging about 1.3%, targeting its highest close since early August and outperforming larger-cap indices.
Among industries, solar, clean energy and regional banks led gains as traders eyed pockets of the markets that would benefit from lower interest rates.
On the macro front, August retail sales provided an upside surprise, growing by 0.1% month-over-month compared to <a href="https://www.benzinga.com/news/econ-s/24/09/40902634/retail-spending-remains-on-solid-footing-but-fed-must-weigh-rate-cuts-impact-on-workers-says-economi">the expected 0.2% decline</a>. This stronger-than-anticipated data slightly reduced the likelihood of a more aggressive 50-basis-point rate cut, with market-implied probabilities for such a move slipping from 67% to 63%, according to the CME FedWatch Tool.
Short-dated Treasury yields rose as expectations for a substantial rate cut moderated. Meanwhile, the dollar strengthened, gaining 0.2%. 
In the commodities market, gold retreated 0.7% from Monday&#8217;s record-high close. Oil prices increased by 1.3% following escalating geopolitical tensions in the Middle East.
Reports indicate a<a href="https://www.benzinga.com/etfs/specialty-etfs/24/09/40903888/simultaneous-pager-explosions-across-lebanon-leave-over-1-000-hezbollah-militants-wounded"> coordinated attack in Lebanon</a> led to thousands of pagers linked to Hezbollah militants being detonated, resulting in numerous casualties within the Iran-backed organization.
Additionally, Iran&#8217;s ambassador to Lebanon is reportedly injured, though the official responsibility for the attack remains unclaimed.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) jumped over 4%, buoyed by positive ETF inflows, signaling renewed investor interest in the digital asset space as interest rates shift. 
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,220.44</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,642.79</td>
<td>0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,441.83</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,636.05</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:38 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091724&amp;t=be2bearmibe3na1">Benzinga Pro</a> platform:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;was 0.1% higher to $563.44.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.1% up to $417.61.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) also rose 0.1% to $473.60.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.2% to $220.28.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.2%. The Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.9%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
<ul>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) surged over 6% after receiving approval from Health Canada for its updated SPIKEVAX COVID-19 vaccine, designed to target the KP.2 sub-lineage of SARS-CoV-2 in individuals aged six months and older.</li>
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) climbed 3.5% following an upgrade from Bank of America, which raised its rating on the stock from Neutral to Buy and increased the price target from $200 to $300.</li>
<li>Hewlett Packard Enterprise Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) advanced nearly 5% after Bank of America also upgraded its rating from Neutral to Buy and boosted the price target from $21 to $24.</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/24/09/40904599/stock-of-the-day-will-apple-bring-the-market-down">Stock Of The Day: Will Apple Bring The Market Down?</a></li>
</ul>
The image was created using artificial intelligence MidJourney.

Sector ETFs

Retail Sales

Small Cap

Federal Reserve

$BTC

Small Caps, Bitcoin Rally As Traders Await Fed Rate Cut; Treasury Yields, US Dollar Tick Up On Strong Retail Sales: What's Driving Markets Tuesday?

Q3 2024 Winners And Losers And My Outlook For Q4

How is SPY stock faring? The SPDR S&P 500 ETF Trust  is down 0.03% in the past 5 days but has risen about 21.4% year-to-date. According to TipRanks...

SPY ETF Update, 1/10/2024

Moderna, Cenra Healthcare enter JV to promote mRNA respiratory vaccine in Taiwan

Top movers as S&P 500 clocks another quarter of growth

Top movers as S&P 500 clocks another quarter of record growth

How is VOO stock faring? The Vanguard S&P 500 ETF is down 0.76% in the past five days but has risen 35.68% over the past year.  According to TipRan...

VOO ETF Update, 10/2/2024

An update from Moderna ( ($MRNA) ) is now available. Moderna, Inc. has announced the appointment of Abbas Hussain to its Board of Directors, effect...

Moderna Enhances Board with Healthcare Veteran Abbas Hussain

Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3

Gritstone downgraded by Jones, B. Riley over cancer vaccine data

How is QQQ stock faring? The Invesco QQQ ETF is down 1% in the past 5 days but has risen about 18% year-to-date.   According to TipRanks' unique ET...

QQQ ETF Update, 10/3/2024

AAPL

ALLE

ASML

AXON

BIIB

BLDR

CBRE

COPX

CRWD

DLTR

DXCM

ERIE

EXPD

FAST

FTNT

GRTS

INTC

LRCX

NVDA

PARA

PAYX

PLTR

SMCI

SOLV

SONY

TSLA

VALE

XLRE

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Legal

Press Releases

Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights – MRNA

MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline

Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna's mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm

Moderna, Inc. Class Action: Levi & Korsinsky Reminds Moderna Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA

Abbas Hussain Joins Moderna's Board of Directors

October 8, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MRNA

A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRNA

Comments

Moderna

Interés en corto

Moderna (NASDAQ:MRNA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL